<DOC>
	<DOCNO>NCT02099123</DOCNO>
	<brief_summary>The STAREE study examine whether treatment statin ( atorvastatin 40mg ) compare placebo prolong overall survival disability free survival amongst healthy elderly people ( ≥70 year ) .</brief_summary>
	<brief_title>A Clinical Trial STAtin Therapy Reducing Events Elderly ( STAREE )</brief_title>
	<detailed_description>Statin therapy show reduce risk vascular event young individual manifest atherosclerotic disease high risk vascular event . However , data derive meta-analyses exist trial suggest efficacy statin may decline sharply amongst 70-75 year age . Insufficient patient age group include major trial certain benefit . Within age group part benefit statin therapy may offset adverse effect include myopathy , development diabetes , cancer cognitive impairment , prevalent elderly event . The use statins 70 age group raise fundamental question purpose preventive drug therapy age group . When preventive agent use context compete mortality , polypharmacy high incidence adverse effect use justified improvement quality life composite measure demonstrate benefit outweighs factor . STAREE determine whether take daily statin therapy ( 40 mg atorvastatin ) extend length disability-free life , determine survival outside permanent residential care , healthy participant age 70 year .</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Men woman age ≥70 year live independently community Willing able provide inform consent accept study requirement ( Note : competent physical ability participate trial assess use KATZ ADL questionnaire ) A history cardiovascular disease ( define myocardial infarction , stroke , peripheral vascular disease , angina , transient ischaemic attack , coronary artery angioplasty and/or stenting , coronary artery bypass graft heart failure ) , A history dementia 3MS score &lt; 78 screening , A history diabetes , Total cholesterol &gt; 7.5 mmol/L , Moderate severe chronic kidney disease ( persistent proteinuria ( Urine albumin : creatinine ratio &gt; 30mg/mmol Urine protein : creatinine ratio &gt; 45 mg/mmol ) 45 and/or eGFR &lt; 45ml/min/1.73m2 ) , Moderate severe liver disease ( persistent elevation transaminases 3 time upper limit normal laboratory reference range ) , Serious intercurrent illness likely cause death within next 5 year terminal cancer obstructive airway disease , Current participation clinical trial ( Note : If yes , exclusion trial involve take drug another intervention ) Absolute contraindication statin therapy , Current use statin therapy lipid lower therapy primary prevention unwilling stop therapy , Current long term permanent use follow cytochrome P450 ( CYP ) 3A4 inhibitor : Amiodarone , Boceprevir , Cimetidine , Cyclosporin , Danazol , Fosamprenavir , Indinavir , Lopinavir + Ritonavir , Erythromycin , Fluconazole , Itraconazole , Ketoconazole .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Survival</keyword>
	<keyword>Functional Disability</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Dementia</keyword>
	<keyword>Cancer</keyword>
</DOC>